Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO 2025-10-18 22:46
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting 2025-04-24 13:17
Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors 2025-03-26 10:45
1